Research Group

Carlo-Stella Group

Oncology Experimental Therapies Lab

Carlo-Stella Group

Carmelo Carlo-Stella

Clinical Group Leader

Through a bedside-to-bench-and-back approach, our translational lab, tightly integrated with the clinical activity of the Lymphoid Malignancies and Cancer Therapeutics Unit of the hospital, investigates the cellular mechanisms involved in relapsed and refractory lymphoma with the aim of better predicting disease evolution and improving treatments response.

Main research areas

Signatures of response to immunotherapy in Diffuse Large B-cell Lymphoma

Novel immunotherapies, including chimeric antigen receptor (CAR) T-cell and bispecific antibodies, became available over the past five years for relapsed and refractory Diffuse Large B-Cell Lymphoma. On average, 50% of patients with relapsed and refractory Diffuse Large B-Cell Lymphoma fail to respond to these novel forms of immunotherapies, thus representing an unmet medical need. To address these issues, we started a translational project based on a personalized multi-omics approach to identify biomarkers for disease response and resistance mechanisms to immunotherapy.

Liquid biopsy for disease outcome prediction and monitoring by circulating tumor DNA

Approaches for staging and response evaluation in Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (cHL) rely upon serial imaging assessments, using positron emission tomography (PET) and computed tomography (CT) scans. However, conventional imaging has suboptimal positive and negative predictive values. The use of cell-free fragments of tumor DNA that are shed into the bloodstream from tumor cells and can be easily and repeatedly obtained is emerging as an easy-to-obtain material assessing somatic cancer mutations. We hypothesize that high-throughput sequencing of circulating tumor (ct)DNA to analyze mutational heterogeneity, as well as genomic evolution (mutNGS), may represent an attractive tool to predict disease outcome, monitor disease response and minimal residual disease, identify molecular determinants of chemorefractory patients and track clonal evolution-driven resistance to checkpoint inhibitors.

Selected publications

Crisafulli L
Haematologica
MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation.
Mariotti J
Bone Marrow Transplant
The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide.
Pouillon L
Aliment Pharmacol Ther
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.
Mariotti J
Eur J Haematol
Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.
Locatelli SL
Clin Cancer Res
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
Righi M
Sci Rep
Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.
Sarina B
Transpl Infect Dis
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Carbone A
Blood
Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?
Spina V
Blood
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Mariotti J
Biol Blood Marrow Transplant
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
Mariotti J
Bone Marrow Transplant
Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.
Mineri R
Mediterr J Hematol Infect Dis
Genomic Integration of HHV-6 Mimicking Viral Reactivation after Autologous Stem Cell Transplantation.
Broccoli A
Haematologica
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Trabanelli S
Nat Commun
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Castagna L
Bone Marrow Transplant
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
Merryman RW
Blood
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Pierdominici M
Oncotarget
Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.
Locatelli SL
Leukemia
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.
Castagna L
Bone Marrow Transplant
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.
Locatelli SL
Sci Rep
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.
Santoro A
J Clin Oncol
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Crocchiolo R
Bone Marrow Transplant
The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.
Bramanti S
Transfusion
Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.
Castagna L
Bone Marrow Transplant
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.
Devillier R
Bone Marrow Transplant
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
Crocchiolo R
Haematologica
Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.
Carbone A
J Pathol
Primary refractory and early-relapsed Hodgkin’s lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Roberto A
Blood
Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.
Castagna L
Bone Marrow Transplant
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.
Crocchiolo R
Transpl Infect Dis
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.
Castagna L
Mediterr J Hematol Infect Dis
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.
Reichel J
Blood
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.
Roberto A
Bone Marrow Transplant
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY.
Pennati M
Int J Cancer
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Necchi A
Ann Oncol
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
Carlo-Stella C
Biomark Med
Microenvironment-related biomarkers and novel targets in classical Hodgkin’s lymphoma.
Castagna L
Bone Marrow Transplant
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas.
Guidetti A
Clin Cancer Res
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Grazia G
Cell Death Dis
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.
Locatelli SL
Leukemia
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
Necchi A
Clin Genitourin Cancer
Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.
Colasanti T
Cell Death Dis
Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes.
Castagna L
Biol Blood Marrow Transplant
Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.
Magni M
Bone Marrow Transplant
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Farina L
Bone Marrow Transplant
Plerixafor ‘on demand’: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.
Farina L
Leuk Lymphoma
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Pierdominici M
FASEB J
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.
Carbone A
Adv Exp Med Biol
The role of inflammation in lymphoma.
Marconi M
Cell Death Dis
Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies.
Devizzi L
J Clin Oncol
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
Locatelli SL
Leukemia
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Giacomini A
Angiogenesis
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.
Carlo-Stella C
PLoS One
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Righi M
PLoS One
(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies.
De Filippi P
Pediatr Blood Cancer
The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
Guidetti A
Br J Haematol
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Lobetti-Bodoni C
Mech Ageing Dev
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.
Tassi E
Clin Cancer Res
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.
Magni M
Am J Blood Res
Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.
Servida F
Invest New Drugs
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Guidetti A
Cancer
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Zappasodi R
Blood
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.
Zappasodi R
Cancer Res
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Viviani S
Leuk Lymphoma
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Magni M
Bone Marrow Transplant
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up.
Lavazza C
Blood
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.
Ruella M
Bone Marrow Transplant
Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status.
Magni M
Leuk Res
Radioimmunotherapy and secondary leukemia: a case report.
De Filippi P
Br J Haematol
Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.
Chiesa C
Eur J Nucl Med Mol Imaging
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Righi M
Lab Invest
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
Dodero A
Blood
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.
Magni M
Bone Marrow Transplant
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.
Di Nicola M
Blood
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
Devizzi L
J Clin Oncol
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Zappasodi R
Haematologica
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Carlo-Stella C
Adv Exp Med Biol
Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells.
Lavazza C
Exp Hematol
Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress Reagent.
Carlo-Stella C
Clin Cancer Res
Targeting TRAIL agonistic receptors for cancer therapy.
Rocci A
Exp Hematol
Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir.
Rossi E
Cancer Biol Ther
Forced expression of RDH10 gene retards growth of HepG2 cells.
Carlo-Stella C
Stem Cells
Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates.
Carlo-Stella C
Hum Gene Ther
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand.
Carlo-Stella C
Exp Hematol
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Carlo-Stella C
Cancer Res
The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
Matteucci P
Haematologica
Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.
Anichini A
Blood
Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines.
Ruffini PA
Curr Gene Ther
Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma.
Dodero A
Exp Hematol
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Ricca I
Leukemia
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.
Di Nicola M
Br J Haematol
High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt’s lymphoma in adults.
Di Nicola M
Clin Cancer Res
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Carlo-Stella C
Blood
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.
Khobta A
Cancer Res
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene.
Carlo-Stella C
Exp Hematol
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone.
Carlo-Stella C
Exp Hematol
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.
Di Nicola M
Haematologica
Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection.
Di Nicola M
Hum Gene Ther
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
Lunghi P
Leukemia
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts.
Gianni AM
Blood
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Magni M
Leuk Res
Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor.
Carlo-Stella C
Cancer Res
Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice.
Di Nicola M
Blood
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.
Buschini A
Biochem Pharmacol
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells.
Cilloni D
Blood
Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation.
Di Nicola M
Br J Haematol
Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex.
Buschini A
Leukemia
Amifostine (WR-2721) selective protection against melphalan genotoxicity.
Fogli M
Exp Hematol
Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis.
Di Ianni M
Cancer Gene Ther
T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection.
Siena S
J Clin Oncol
Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.
Carlo-Stella C
Exp Hematol
Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor.
Bonati A
Cancer Res
Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias.
Bordignon C
Haematologica
Cell therapy: achievements and perspectives.
Lo Coco F
Blood
Therapy of molecular relapse in acute promyelocytic leukemia.
Rizzo MT
Cancer Res
Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.
Poli P
Toxicol Lett
DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay.
Di Nicola M
Hum Gene Ther
Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes.
Carlo-Stella C
Blood
Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
Siena S
Haematologica
New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia.
Cilloni D
Bone Marrow Transplant
Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing.
Aglietta M
Haematologica
Ex vivo expansion of hematopoietic cells and their clinical use.
Cesana C
Haematologica
The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase.
Cesana C
Bone Marrow Transplant
CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Savoldo B
Leukemia
Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.
Almici C
Leukemia
Biologic and phenotypic analysis of early hematopoietic progenitor cells in umbilical cord blood.
Di Ianni M
Leuk Res
Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector.
Carlo-Stella C
Bone Marrow Transplant
Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.
Rizzoli V
Crit Rev Oncol Hematol
Stem cell manipulation: why and how performing peripheral blood progenitor cell purging.
Almici C
Bone Marrow Transplant
Clonogenic capacity and ex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation.
Carlo-Stella C
Haematologica
Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Cesana C
Stem Cells
In vitro growth of mobilized peripheral blood progenitor cells is significantly enhanced by stem cell factor.
Rizzo MT
Blood
Arachidonic acid mediates interleukin-1 and tumor necrosis factor-alpha-induced activation of the c-jun amino-terminal kinases in stromal cells.
Carlo-Stella C
Haematologica
Stem cells and stem cell transplantation.
Carlo-Stella C
Blood
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Almici C
Blood
Detection of maternal progenitor cells in human umbilical cord blood by single-colony karyotyping.
Carlo-Stella C
Br J Haematol
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells.
Bonati A
Exp Hematol
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life.
Almici C
Acta Haematol
Density separation and cryopreservation of umbilical cord blood cells: evaluation of recovery in short-and long-term cultures.
Rosti V
Blood
Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors.
Rizzo MT
Blood
Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process.
Almici C
Stem Cells
Density separation of umbilical cord blood and recovery of hemopoietic progenitor cells: implications for cord blood banking.
Almici C
Bone Marrow Transplant
Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Rizzoli V
Exp Hematol
Stem cell purging: an intriguing dilemma.
Dotti G
Haematologica
Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Carlo-Stella C
Bone Marrow Transplant
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Carlo-Stella C
Blood
Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients.
Balduini CL
Br J Haematol
Acquired cyclic thrombocytopenia-thrombocytosis with periodic defect of platelet function.
Almici C
Bone Marrow Transplant
Counterflow centrifugal elutriation: present and future.
Carlo-Stella C
Blood
Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Rizzoli V
Leukemia
Autologous bone marrow transplantation in acute myelogenous leukemia.
Carlo-Stella C
Exp Hematol
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C
Bone Marrow Transplant
In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte–macrophage colony-stimulating factor.
Bergamaschi G
Leukemia
Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia.
Ottmann OG
Exp Hematol
Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells.
Bergamaschi G
Br J Haematol
Establishment and characterization of a B-cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers.
Almici C
Haematologica
Human peripheral blood mononuclear cell subfractionation using counterflow centrifugation elutriation.
Carlo-Stella C
Leukemia
Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors.
Bergamaschi G
Leukemia
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia.
Rosti V
Haematologica
In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome.
Carlo-Stella C
Leukemia
Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor.
Carlo-Stella C
Haematologica
In vitro growth of bone marrow-derived multipotent and lineage-restricted hematopoietic progenitor cells in myelodysplastic syndromes.
Dezza L
Leukemia
Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies.
Ganser A
Blood
Establishment of two Epstein-Barr virus negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma.
Carlo-Stella C
Blood
Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM).
Giordano M
Haematologica
Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells.
Dezza L
Br J Haematol
Effects of recombinant human H-subunit and L-subunit ferritins on in vitro growth of human granulocyte-monocyte progenitors.
Carlo Stella C
Leukemia
Recombinant gamma-interferon induces in vitro monocytic differentiation of blast cells from patients with acute nonlymphocytic leukemia and myelodysplastic syndromes.
Stella CC
Haematologica
“In vitro” megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura.
Carlo-Stella C
Blood
Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia.
Ganser A
Blood
Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells.
Stella CC
J Clin Invest
Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome.
Carlo Stella C
Haematologica
Clinical relevance of two in vitro tests based on CFU-GM assay in the study of granulopoietic failure.
Carlo Stella C
Haematologica
Cell- and humoral-mediated granulopoietic failure detected by CFU-GM assay in one case of Felty’s syndrome unresponsive to prednisolone treatment.
Ghizzi A
Haematologica
Significance of marrow-blood barrier for CFU-GM in patients with acute nonlymphoid leukemia (AnLL).
Bobbio Pallavicini E
Haematologica
Circulating granulocytic progenitor cell (CFU-GM) cultures in a long surviving case of smouldering leukemia.
Ghizzi A
Haematologica
Spectrum of bone marrow cluster- and colony-forming units in healthy adult subjects.
Dezza L
Haematologica
Myelodysplastic syndrome with monosomy 7 in adulthood: a distinct preleukaemic disorder.
Ghizzi A
Haematologica
“Overshoot” phenomenon in circulating granulocytic progenitor cell growth during remission of blast crisis in a case of CML.
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts

Group members

Carlo-Stella Group
Carmelo Carlo-Stella

Clinical Group Leader

Carlo-Stella Group
Giustina Casagrande

Postdoc fellow

Carlo-Stella Group
Martina Di Trani

Technician

Carlo-Stella Group
Chiara Signori

PhD student